Why High-Flying Aurinia Stock Could Still Be Dirt Cheap

If 2017 ended today, Aurinia Pharmaceuticals would rank as one of the biggest winners of the year among biopharmaceutical stocks. Aurinia’s share price has more than tripled so far this year.

Is Aurinia overpriced after such tremendous gains? Some might think so.